Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 106 to 120 of 201 results for advanced breast cancer

  1. Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema (HTG717)

    Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.

  2. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  3. Spinal metastases and metastatic spinal cord compression (NG234)

    This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.

  4. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

  5. OSNA for colon cancer staging (MIB77)

    NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging

  6. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  7. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer (TA1130)

    Evidence-based recommendations on talazoparib (Talzenna) with enzalutamide (Xtandi) for untreated hormone-relapsed metastatic prostate cancer.

  8. Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

    Awaiting development Reference number: GID-TA11862 Expected publication date: TBC

  9. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

    Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected non-small-cell lung cancer in adults.

  10. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

  11. SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver (HTG291)

    Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

  12. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued Reference number: GID-TA10570

  13. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

  14. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued Reference number: GID-TAG432

  15. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development Reference number: GID-TA11535 Expected publication date: TBC